Hexetidine (NSC-17764)
(Synonyms: 海克替啶,NSC-17764) 目录号 : GC33958
Hexetidine is an anti-bacterial and anti-fungal agent with local anesthetic, astringent, deodorant and antiplaque activity.
Cas No.:141-94-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Hexetidine is an anti-bacterial and anti-fungal agent with local anesthetic, astringent, deodorant and antiplaque activity.
| Cas No. | 141-94-6 | SDF | |
| 别名 | 海克替啶,NSC-17764 | ||
| Canonical SMILES | NC1(C)CN(CC(CC)CCCC)CN(CC(CC)CCCC)C1 | ||
| 分子式 | C21H45N3 | 分子量 | 339.6 |
| 溶解度 | DMSO : ≥ 29 mg/mL (85.39 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9446 mL | 14.7232 mL | 29.4464 mL |
| 5 mM | 0.5889 mL | 2.9446 mL | 5.8893 mL |
| 10 mM | 0.2945 mL | 1.4723 mL | 2.9446 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
The effectiveness of various gargle formulations and salt water against SARS-CoV-2
Sci Rep 2021 Oct 15;11(1):20502.PMID:34654867DOI:10.1038/s41598-021-99866-w.
The COVID-19 is difficult to contain due to its high transmissibility rate and a long incubation period of 5 to 14 days. Moreover, more than half of the infected patients were young and asymptomatic. Virus transmission through asymptomatic patients is a major challenge to disease containment. Due to limited treatment options, preventive measures play major role in controlling the disease spread. Gargling with antiseptic formulation may have potential role in eliminating the virus in the throat. Four commercially available mouthwash/gargle formulations were tested for virucidal activity against SARS-CoV-2 in both clean (0.3 g/l BSA) and dirty (0.3 g/l BSA + 3 mL/L human erythrocytes) conditions at time points 30 and 60 s. The virus was isolated and propagated in Vero E6 cells. The cytotoxicity of the products to the Vero E6 was evaluated by kill time assay based on the European Standard EN14476:2013/FprA1:2015 protocol. Virus titres were calculated as 50% tissue culture infectious dose (TCID50/mL) using the Spearman-Karber method. A reduction in virus titer of 4 log10 corresponds to an inactivation of ≥ 99.99%. Formulations with cetylperidinium chloride, chlorhexidine and hexitidine achieved > 4 log10 reduction in viral titres when exposed within 30 s under both clean and dirty conditions. Thymol formulations achieved only 0.5 log10 reduction in viral titres. In addition, salt water was not proven effective. Gargle formulations with cetylperidinium chloride, chlorhexidine and Hexetidine have great potential in reducing SAR-CoV-2 at the source of entry into the body, thus minimizing risk of transmission of COVID-19.
The effect of Hexetidine mouthwash on the prevention of plaque and gingival inflammation: a systematic review
Int J Dent Hyg 2011 Aug;9(3):182-90.PMID:21356020DOI:10.1111/j.1601-5037.2010.00478.x.
Objective: To review the literature concerning hexetidine-containing mouthwash as a monotherapy or as an adjunct to oral hygiene in the prevention of plaque accumulation and gingival inflammation. Materials and methods: PubMed-MEDLINE and the Cochrane-CENTRAL were searched through January 2010 to identify appropriate studies. The primary outcome measurements were plaque accumulation and gingivitis parameters. Results: Independent screening of titles and abstracts of 168 papers resulted in six publications that met the eligibility criteria. Mean values and standard deviations were obtained by data extraction. Descriptive comparisons are presented for Hexetidine mouthwash and control mouthwashes (chlorhexidine and placebo). Conclusions: Considering the potential benefits in the light of the observed side effects, Hexetidine appears to be a poor alternative to chlorhexidine.
The effects of Hexetidine (Oraldene) on the adherence of Candida albicans to human buccal epithelial cells in vitro and ex vivo and on in vitro morphogenesis
Pharm Res 1997 Dec;14(12):1765-71.PMID:9453066DOI:10.1023/a:1012140131757.
Purpose: This study reports the effects of Hexetidine (Oraldene) on two virulence attributes of Candida albicans, namely, in vitro and ex vivo adherence of yeast cells to buccal epithelial cells (BEC) and in vitro morphogenesis. Methods: The effects of Hexetidine treatment of either yeast cells (stationary and exponential phases) or BEC on Candidal adherence, in terms of viable and non-viable adherent yeast cells, were evaluated using an acridine orange stain in conjunction with fluorescence microscopy. Ex vivo anti-adherence effects were determined by rinsing BEC in vivo with Hexetidine (0.1%), removal of BEC after defined periods and inclusion in the adherence assay. The effects of Hexetidine on morphogenesis were evaluated using light microscopy. Yeast cell viability following exposure to a range of concentration of Hexetidine (0.005-0.1% v/v) for defined periods was determined following serial dilution and enumeration on solid media. Results: Treatment of stationary and exponential phase yeast cells or BEC with Hexetidine (0.1%) for a range of times (10-300 s) or, alternatively, with a range of concentrations of Hexetidine (0.005-0.1%) for a fixed time (30s) significantly decreased the resultant Candidal/ epithelial adhesion. No correlations were observed between reduced adherence and either time of treatment or Hexetidine concentration. In vivo treatment of BEC with Hexetidine (0.1%) for 30s resulted in prolonged and significant reductions in the ex vivo adherence of both viable and non-viable yeast cells for periods of up to (and including) four hours post-rinsing. Treatment of C. albicans blastospores with Hexetidine (0.05, 0.1% v/v) for 10s and 30s totally inhibited Candida morphogenesis, whereas treatment with lower antiseptic concentrations significantly reduced the extent of Candida morphogenesis and the rate of hyphal development. The effects of Hexetidine on yeast cell viability were both concentration and time-dependent. Conclusions: The reduced adherence of C. albicans to BEC and the modification or inhibition of morphogenesis following exposure to Hexetidine suggests a clinical role for Hexetidine in the prophylaxis of both superficial candidosis and the systemic complications resulting from invasion of sub-epithelial tissue.
Determination of the salivary retention of Hexetidine in-vivo by high-performance liquid chromatography
J Pharm Pharmacol 2000 Nov;52(11):1355-9.PMID:11186243DOI:10.1211/0022357001777504.
The non-antibiotic antimicrobial agent Hexetidine is widely used at a concentration of 0.1% w/v as an oral rinse to reduce the number of viable microorganisms within the oral cavity. However, following use, the available concentration of Hexetidine in the oral cavity declines with time, thus compromising the resultant antimicrobial activity. It is, therefore, desirable to determine the persistence of the agent in the oral cavity by quantification of the drug concentration in saliva, thus enabling prediction of its antimicrobial activity in the oral environment. A rapid reverse-phase HPLC method was therefore developed and validated for Hexetidine in aqueous solution (Oraldene) and in saliva samples collected from volunteers post-rinsing with 15 mL of Hexetidine oral rinse for 30s. The HPLC assay was sufficiently sensitive to accurately detect Hexetidine in saliva up to 25 min after in-vivo use of a commercial oral rinse. Furthermore, it was possible to detect Hexetidine below the published minimum inhibitory concentrations (MICs) for a selection of microorganisms. From these data a first-order elimination rate constant of Hexetidine from the oral cavity was determined post-rinsing in each of six volunteers. The validated HPLC assay method presented is useful for the assay of Hexetidine in the oral cavity both at and below MICs. The first-order elimination rate constant shows significant variation between volunteers.
Effect of the most common wound antiseptics on human skin fibroblasts
Clin Exp Dermatol 2022 Aug;47(8):1543-1549.PMID:35466431DOI:10.1111/ced.15235.
Background: Antiseptics are used for the cleansing of acute or chronic wounds to eliminate micro-organisms from the wound bed. However, they have effects on the skin cells. Aim: To determine the effects of Hexetidine, povidone-iodine (PI), undecylenamidopropyl-betaine/polyhexanide (UBP), chlorhexidine, disodium eosin and hydrogen peroxide on human skin fibroblasts. Methods: CCD-1064Sk cells were treated with Hexetidine, PI, UBP, chlorhexidine, disodium eosin or hydrogen peroxide. Spectrophotometry was used to measure cell viability and flow cytometry was used to study apoptosis and necrosis after the treatment. In vitro wound scratch assays were performed to determine the gap closure. Results: All antiseptics significantly reduced the viability of human skin fibroblasts compared with controls. The percentage wound closure was lower with Hexetidine, PI and UBP. The scratch assay could not be measured after treatments with chlorhexidine, disodium eosin or hydrogen peroxide, owing to their cytotoxicity. The apoptosis/necrosis experiments evidenced a significant reduction in viable cells compared with controls. An increased percentage of apoptotic cells was observed after treatment with all antiseptics. Compared with controls, the percentage of necrotic cells was significantly increased with all antiseptics except for Hexetidine. Conclusion: The proliferation, migration and viability of human skin fibroblasts are reduced by treatment with Hexetidine, PI, UBP, chlorhexidine, disodium eosin and hydrogen peroxide.